GSK-2983559

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameGSK-2983559
Drug Alias NameGSK-2983559
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase RIPK2 inhibitors
TargetsSerine/threonine-protein kinase RIPK2
Therapy Area/IndicationsInflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsInflammatory Bowel Diseases

Other Information

ATC CodeN/A
Related LinksN/A